PBI17 BUDGET IMPACT ANALYSIS OF INTRODUCTION OF RITUXIMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE

Value in Health ◽

10.1016/j.jval.2020.04.084 ◽

2020 ◽

Vol 23 ◽

pp. S16-S17

Author(s):

V. Ektare ◽

R. Liu ◽

J. Stephens ◽

A. Al Taie ◽

A. Shelbaya

Keyword(s):

United States ◽

Impact Analysis ◽

Budget Impact ◽

The United States ◽

Budget Impact Analysis ◽

Payer Perspective

Download Full-text

PBI7 BUDGET IMPACT ANALYSIS OF INTRODUCTION OF BEVACIZUMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE

Value in Health ◽

10.1016/j.jval.2020.04.076 ◽

2020 ◽

Vol 23 ◽

pp. S15

Author(s):

V. Ektare ◽

R. Liu ◽

J. Stephens ◽

A. Shelbaya ◽

J. Yang

Keyword(s):

United States ◽

Impact Analysis ◽

Budget Impact ◽

The United States ◽

Budget Impact Analysis ◽

Payer Perspective

Download Full-text

Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective

Journal of Managed Care & Specialty Pharmacy ◽

10.18553/jmcp.2018.18094 ◽

2019 ◽

Vol 25 (1) ◽

pp. 94-101 ◽

Author(s):

Holly Trautman ◽

Erika Szabo ◽

Elizabeth James ◽

Boxiong Tang

Keyword(s):

United States ◽

Impact Analysis ◽

Budget Impact ◽

The United States ◽

Budget Impact Analysis ◽

Payer Perspective ◽

Biosimilar Filgrastim

Download Full-text

PCN71 Budget IMPACT Analysis of Zanubrutinib for the Treatment of Adult Patients with Mantle Cell Lymphoma WHO Have Received at Least One PRIOR Therapy from the Payer Perspective in the United States

Value in Health ◽

10.1016/j.jval.2020.08.208 ◽

2020 ◽

Vol 23 ◽

pp. S434

Author(s):

R. Liu ◽

Y.C. Yeh ◽

K. Yang ◽

X. Gao ◽

M. Balk ◽

...

Keyword(s):

United States ◽

Mantle Cell Lymphoma ◽

Impact Analysis ◽

Budget Impact ◽

Cell Lymphoma ◽

The United States ◽

Adult Patients ◽

Prior Therapy ◽

Payer Perspective ◽

Download Full-text

PCN28 Budget Impact Analysis of Everolimus for ER+, HER2- Metastatic Breast Cancer Patients in the United States

Value in Health ◽

10.1016/j.jval.2012.03.1145 ◽

2012 ◽

Vol 15 (4) ◽

pp. A212

Author(s):

J. Xie ◽

M. Diener ◽

G. De ◽

E.Q. Wu ◽

M. Namjoshi

Keyword(s):

Breast Cancer ◽

United States ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Impact Analysis ◽

Budget Impact ◽

Metastatic Breast ◽

The United States ◽

Budget Impact Analysis ◽

Breast Cancer Patients

Download Full-text

Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2%

Journal of Medical Economics ◽

10.1080/13696998.2018.1470520 ◽

2018 ◽

Vol 21 (8) ◽

pp. 770-777 ◽

Author(s):

Ryan Clark ◽

Duygu Bozkaya ◽

Mark Levenberg ◽

Steven Faulkner ◽

Timothy W. Smith ◽

...

Keyword(s):

United States ◽

Atopic Dermatitis ◽

Topical Treatment ◽

Impact Analysis ◽

Budget Impact ◽

The United States ◽

Budget Impact Analysis ◽

Treatment Utilization

Download Full-text

PND40 BUDGET IMPACT ANALYSIS OF GALCANEZUMAB-GNLM FOR THE PREVENTIVE TREATMENT OF PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE IN THE UNITED STATES

Value in Health ◽

10.1016/j.jval.2019.04.1313 ◽

2019 ◽

Vol 22 ◽

pp. S277

Author(s):

S.A. Foster ◽

S. Milev ◽

M. Hoog ◽

O. Mason ◽

A. Sardesai ◽

...

Keyword(s):

United States ◽

Impact Analysis ◽

Budget Impact ◽

Preventive Treatment ◽

The United States ◽

Episodic Migraine ◽

Budget Impact Analysis

Download Full-text

PMD7 Budget Impact Analysis of Transcutaneous Afferent Patterned Stimulation Therapy for the Treatment of Essential Tremor in the United States

Value in Health ◽

10.1016/j.jval.2021.04.605 ◽

2021 ◽

Vol 24 ◽

pp. S124

Author(s):

J. Jandu ◽

F. Naylor ◽

E. McAughey ◽

A. Samiian ◽

M. Blackney ◽

...

Keyword(s):

United States ◽

Essential Tremor ◽

Impact Analysis ◽

Budget Impact ◽

The United States ◽

Budget Impact Analysis

Download Full-text

Expanded HIV Screening in the United States: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis

Value in Health ◽

10.1111/j.1524-4733.2010.00763.x ◽

2010 ◽

Vol 13 (8) ◽

pp. 893-902 ◽

Author(s):

Erika G. Martin ◽

A. David Paltiel ◽

Rochelle P. Walensky ◽

Bruce R. Schackman

Keyword(s):

United States ◽

Impact Analysis ◽

Budget Impact ◽

The United States ◽

Budget Impact Analysis ◽

Download Full-text

Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States

Infectious Diseases and Therapy ◽

10.1007/s40121-021-00583-8 ◽

2022 ◽

Author(s):

Yiling Jiang ◽

Eric M. Sarpong ◽

Pamela Sears ◽

Engels N. Obi

Keyword(s):

United States ◽

Impact Analysis ◽

Budget Impact ◽

The United States ◽

Budget Impact Analysis ◽

Clostridioides Difficile ◽

Clostridioides Difficile Infection

Download Full-text

PUK5 Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the United States

Value in Health ◽

10.1016/j.jval.2021.04.1173 ◽

2021 ◽

Vol 24 ◽

pp. S234-S235

Author(s):

J. Nesheim ◽

J.V. Chen ◽

J.C. Gahn ◽

P. Mudd

Keyword(s):

United States ◽

Overactive Bladder ◽

Impact Analysis ◽

Budget Impact ◽

The United States ◽

Budget Impact Analysis

Download Full-text